Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on August 8, 2005

Circulation. 2005
Published online before print August 8, 2005, doi: 10.1161/CIRCULATIONAHA.104.529552
A more recent version of this article appeared on August 16, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/7/1040    most recent
CIRCULATIONAHA.104.529552v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Royen, N.
Right arrow Articles by Buschmann, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Royen, N.
Right arrow Articles by Buschmann, I.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Angiogenesis
Right arrow Smooth muscle proliferation and differentiation
Right arrow Peripheral vascular disease
Right arrow Exercise/exercise testing/rehabilitation
Right arrow Other Treatment

Submitted on December 19, 2004
Revised on April 10, 2005
Accepted on May 3, 2005

START Trial. A Pilot Study on STimulation of ARTeriogenesis Using Subcutaneous Application of Granulocyte-Macrophage Colony-Stimulating Factor as a New Treatment for Peripheral Vascular Disease

Niels van Royen MD, PhD*, Stephan H. Schirmer MD, Bektas Atasever MD, Casper Y.H. Behrens MD, Dirk Ubbink MD, PhD, Eva E. Buschmann MD, Michiel Voskuil MD, PhD, Pieter Bot MD, Imo Hoefer MD, PhD, Reinier O. Schlingemann MD, PhD, Bart J. Biemond MD, PhD, J. G. Tijssen PhD, Christoph Bode MD, Wolfgang Schaper MD, PhD, Jacques Oskam MD, PhD, Dink A. Legemate MD, PhD, Jan J. Piek MD, PhD, and Ivo Buschmann MD

From the Department of Cardiology (N.v.R., B.A., C.Y.H.B., M.V., P.B., J.G.T., J.J.P.), the Department of Vascular Surgery (D.U., D.A.L.), the Department of Ophthalmology (R.O.S.), and the Department of Hematology (B.J.B.), University of Amsterdam, the Netherlands; the Department of Cardiology, University of Freiburg, Germany (S.H.S., E.E.B., I.H., C.B., I.B.); the Department of Experimental Cardiology, Max Planck Institute, Bad Nauheim, Germany (W.S.); and the Department of Vascular Surgery, Rijnland Hospital, Leiderdrop, the Netherlands (J.O.).

* To whom correspondence should be addressed. E-mail: n.vanroyen{at}amc.uva.nl.

Background--Granulocyte-macrophage colony-stimulating factor (GM-CSF) was recently shown to increase collateral flow index in patients with coronary artery disease. Experimental models showed beneficial effects of GM-CSF on collateral artery growth in the peripheral circulation. Thus, in the present study, we evaluated the effects of GM-CSF in patients with peripheral artery disease.

Methods and Results--A double-blinded, randomized, placebo-controlled study was performed in 40 patients with moderate or severe intermittent claudication. Patients were treated with placebo or subcutaneously applied GM-CSF (10 µg/kg) for a period of 14 days (total of 7 injections). GM-CSF treatment led to a strong increase in total white blood cell count and C-reactive protein. Monocyte fraction initially increased but thereafter decreased significantly as compared with baseline. Both the placebo group and the treatment group showed a significant increase in walking distance at day 14 (placebo: 127±67 versus 184±87 meters, P=0.03, GM-CSF: 126±66 versus 189±141 meters, P=0.04) and at day 90. Change in walking time, the primary end point of the study, was not different between groups. No change in ankle-brachial index was found on GM-CSF treatment at day 14 or at day 90. Laser Doppler flowmetry measurements showed a significant decrease in microcirculatory flow reserve in the control group (P=0.03) and no change in the GM-CSF group.

Conclusions--The present study does not support the use of GM-CSF for treatment of patients with moderate or severe intermittent claudication. Issues that need to be addressed are dosing, the selection of patients, and potential differences between GM-CSF effects in the coronary and the peripheral circulation.


Key words: angiogenesis • collateral circulation • growth substances • leukocytes • peripheral vascular disease




This article has been cited by other articles:


Home page
CirculationHome page
P. Meier, S. Gloekler, S. F. de Marchi, A. Indermuehle, T. Rutz, T. Traupe, H. Steck, R. Vogel, and C. Seiler
Myocardial Salvage Through Coronary Collateral Growth by Granulocyte Colony-Stimulating Factor in Chronic Coronary Artery Disease: A Controlled Randomized Trial
Circulation, October 6, 2009; 120(14): 1355 - 1363.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman
Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance
Circulation, June 9, 2009; 119(22): 2928 - 2935.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen
Stimulation of collateral artery growth: travelling further down the road to clinical application
Heart, February 1, 2009; 95(3): 191 - 197.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
I. Al Mheid and A. A. Quyyumi
Cell Therapy in Peripheral Arterial Disease
Angiology, January 1, 2009; 59(6): 705 - 716.
[Abstract] [PDF]


Home page
J. Leukoc. Biol.Home page
M. C. van Oostrom, O. van Oostrom, P. H. A. Quax, M. C. Verhaar, and I. E. Hoefer
Insights into mechanisms behind arteriogenesis: what does the future hold?
J. Leukoc. Biol., December 1, 2008; 84(6): 1379 - 1391.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. H. Schirmer, J. O. Fledderus, P. T.G. Bot, P. D. Moerland, I. E. Hoefer, J. Baan Jr, J. P.S. Henriques, R. J. van der Schaaf, M. M. Vis, A. J.G. Horrevoets, et al.
Interferon-{beta} Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice
Circ. Res., May 23, 2008; 102(10): 1286 - 1294.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
C Kalka and I. Baumgartner
Gene and stem cell therapy in peripheral arterial occlusive disease
Vascular Medicine, May 1, 2008; 13(2): 157 - 172.
[Abstract] [PDF]


Home page
CirculationHome page
C. J. White and W. A. Gray
Endovascular Therapies for Peripheral Arterial Disease: An Evidence-Based Review
Circulation, November 6, 2007; 116(19): 2203 - 2215.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
H.R.S. Girn, N.M. Orsi, and S. Homer-Vanniasinkam
An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease
Vascular Medicine, November 1, 2007; 12(4): 299 - 309.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. Grundmann, N. van Royen, G. Pasterkamp, N. Gonzalez, E. J. Tijsma, J. J. Piek, and I. E. Hoefer
A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate Collateral Artery Growth Via Transforming Growth Factor-{beta}1 Release
J. Am. Coll. Cardiol., July 24, 2007; 50(4): 351 - 358.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Yla-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen
Vascular Endothelial Growth Factors: Biology and Current Status of Clinical Applications in Cardiovascular Medicine
J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1015 - 1026.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Tan, H. Shao, D. Eton, Z. Yang, L. Alonso-Diaz, H. Zhang, A. Schulick, A. S. Livingstone, and H. Yu
Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor
Cardiovasc Res, March 1, 2007; 73(4): 823 - 832.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
R. G. Shaffer, S. Greene, A. Arshi, G. Supple, A. Bantly, J. S Moores, M. S Parmacek, and E. R Mohler III
Effect of acute exercise on endothelial progenitor cells in patients with peripheral arterial disease
Vascular Medicine, November 1, 2006; 11(4): 219 - 226.
[Abstract] [PDF]


Home page
Circ. Res.Home page
G. L. Semenza
Therapeutic Angiogenesis: Another Passing Phase?
Circ. Res., May 12, 2006; 98(9): 1115 - 1116.
[Full Text] [PDF]


Home page
INT J LOW EXTREM WOUNDSHome page
J. Emmerich
Current State and Perspective on Medical Treatment of Critical Leg Ischemia: Gene and Cell Therapy
International Journal of Lower Extremity Wounds, December 1, 2005; 4(4): 234 - 241.
[Abstract] [PDF]